Indian drugmaker Dr Reddy’s Laboratories (BSE: 500124) has completed the trial program for its proposed rituximab biosimilar candidate, and will move ahead with global regulatory interactions.
Data supporting the candidate, DRL_RI, will be submitted in the USA, Europe and other regions.
Since the expiry of patents protecting the therapy, developed by Swiss giant Roche (ROG: SIX) and marketed under the Rituxan and MabThera brands, biosimilar competition has increased in the USA and around the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze